JGC
PSTX

J. Goldman & Co’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

J. Goldman & Co’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-301,391
Closed -$2.2M – 467
2021
Q3 		$2.2M Buy
301,391
+98,890
+49% +$849K 0.11% 181
2021
Q2 		$2.03M Buy
+202,501
New +$1.81M 0.08% 221

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

J. Goldman & Co's PSTX Position: Q4 2021 in Review

J. Goldman & Co sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2021, closing a stake of 301,391 shares — an estimated $2.2M sold.

J. Goldman & Co first reported a position in PSTX in Q2 2021 and held it in 2 quarters. The position peaked at $2.2M in Q3 2021. 66 funds tracked by Wall St. Rank hold PSTX as of Q4 2021.

  • J. Goldman & Co reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • J. Goldman & Co sold 301,391 Poseida Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $2.2M.
  • J. Goldman & Co first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • J. Goldman & Co's Poseida Therapeutics, Inc. Common Stock position peaked at $2.2M in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2021.

Based on J. Goldman & Co's 13F filing for Q4 2021, filed 14 Feb 2022.